C H Ohlmann

Summary

Country: Germany

Publications

  1. Ohlmann C, Thelen P. [Antihormonal therapy in prostate cancer : Side effects]. Urologe A. 2017;56:465-471 pubmed publisher
    ..Therefore, the clever, timely use of androgen deprivation or even the use of a bipolar androgen therapy should enable reversal of resistance to again render tumor cells sensitive to androgen-deprivation therapy. ..
  2. de Mello Martins A, Allegretta G, Unteregger G, Haupenthal J, Eberhard J, Hoffmann M, et al. CYP17A1-independent production of the neurosteroid-derived 5?-pregnan-3?,6?-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone. J Steroid Biochem Mol Biol. 2017;174:183-191 pubmed publisher
    ..To which extent these processes are responsible or involved in the development of resistance to Abi, needs to be further elucidated. ..
  3. Ohlmann C, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, et al. Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled tria. Trials. 2017;18:457 pubmed publisher
    ..ClinicalTrials.gov, ID: NCT02077634 . Registered on 9 December 2013. ..
  4. Ohlmann C. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy]. Urologe A. 2017;56:1424-1429 pubmed publisher
    ..Based on the current evidence, it is not possible to decide which patient may benefit from chemohormonal treatment and who will benefit from the combination of ADT plus abiraterone/prednisone...

Detail Information

Publications4

  1. Ohlmann C, Thelen P. [Antihormonal therapy in prostate cancer : Side effects]. Urologe A. 2017;56:465-471 pubmed publisher
    ..Therefore, the clever, timely use of androgen deprivation or even the use of a bipolar androgen therapy should enable reversal of resistance to again render tumor cells sensitive to androgen-deprivation therapy. ..
  2. de Mello Martins A, Allegretta G, Unteregger G, Haupenthal J, Eberhard J, Hoffmann M, et al. CYP17A1-independent production of the neurosteroid-derived 5?-pregnan-3?,6?-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone. J Steroid Biochem Mol Biol. 2017;174:183-191 pubmed publisher
    ..To which extent these processes are responsible or involved in the development of resistance to Abi, needs to be further elucidated. ..
  3. Ohlmann C, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, et al. Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled tria. Trials. 2017;18:457 pubmed publisher
    ..ClinicalTrials.gov, ID: NCT02077634 . Registered on 9 December 2013. ..
  4. Ohlmann C. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy]. Urologe A. 2017;56:1424-1429 pubmed publisher
    ..Based on the current evidence, it is not possible to decide which patient may benefit from chemohormonal treatment and who will benefit from the combination of ADT plus abiraterone/prednisone...